Neurologic diseases and neurogenetics

Summary

This group undertakes the challenges of developing advanced treatments for patients with movement disorders, refractory epilepsy, neuropathies, myasthenia, myopathies, etc., in addition to the work carried out with the Multiple Sclerosis Unit and the Multidisciplinary Unit for Patients with Amyotrophic Lateral Sclerosis (thanks to the collaboration with the Miquel Valls Foundation).he group works in the development of new diagnostic and prognostic biomarkers and clínical, epidemiological studies in neurologial diseases.

619 Publications

Strategic lines

Biomarkers in neurological disease: ALS, MS, Alzheimer's Disease...
New therapeutic strategies in Neurological Diseases
Epidemiology of Neurological Disease: ALS, neurovascular disorders, dementia, Multiple Sclerosis
Lexical access disorders in speech production
Prothrombotic mechanisms in patients with Stroke
Neurophysiological markers in postanoxic patients
Neuronal networks and Epilepsy
Personalized and Precision Medicine in neurological disease
Prognostic studies in movement disorders, multiple sclerosis, ALS, neurovascular, dementia...

Selected Publications

Muñoz Vendrell,A;Campoy,S;Caronna,E;Alpuente,A;Torres Ferrus,M;Nieves Castellanos,C;Olivier,M et al, Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients., J. Headache Pain, 2023;24(1):63-63, doi:10.1186/s10194-023-01585-2
Arroyo Pereiro,P;García Serrano,L;Morandeira,F;Urban,B;Mas,V;Framil,M;León,I et al, Kappa free light chains index in multiple sclerosis very long-term prognosis, Front. Immunol., 2023;141223514-1223514, doi:10.3389/fimmu.2023.1223514
Van Daele,SH;Moisse,M;van Vugt,J;Zwamborn,R;van der Spek,R;van Rheenen,W;Van Eijk,K et al, Genetic variability in sporadic amyotrophic lateral sclerosis., Brain, 2023;00(9):1-10, doi:10.1093/brain/awad120
Martakis,K;Claassen,J;Gascon Bayari,J;Goldschagg,N;Hahn,A;Hassan,A;Hennig,A et al, Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses, Neurology, 2023;100(10):1072-1083, doi:10.1212/WNL.0000000000201660
Sarraj,A;Hassan,AE;Abraham,MG;Ortega Gutierrez,S;Kasner,SE;Hussain,MS;Chen,MC et al, Trial of Endovascular Thrombectomy for Large Ischemic Strokes, N. Engl. J. Med., 2023;388(14):1259-1271, doi:10.1056/NEJMoa2214403

Selected Projects

MCI22004. Clinical trial to evaluate the administration of ApTOLL in ambulances and the neuroprotective effect in stroke patients. RACETOLL. Ministerio de Ciencia e Innovación. Budget: 487.992,8€. 2022-2025. PI: Cardona Portela, Pere.
MCI23008. NexTOLL: A Phase IIb Clinical trial to the evaluate neuroprotective effect of ApTOLL in stroke patients. Ministerio de Ciencia e Innovación. Budget: 485.715,5€. 2023-2026. PI: Cardona Portela, Pere.
INT23017. EPIDEMIOLOGICAL STUDY OF ALS IN COLOMBIA (SOUTH AMERICA) AND ETHIOPIA (AFRICA). ALS Society of Canada ALS CAD. Budget: 65.802,5€. 2024-2025. PI: POVEDANO PANADES, MONICA.
HUB-NEU-2019-01. Ensayo clínico de eficacia y seguridad de efavirenz en pacientes diagnosticados de Niemann-Pick C del adulto con deterioro cognitivo : Eudra CT 2019-004498-18. Fundación Niemann-Pick España. Budget: 80.000€. 2022-2024. PI: Gascón Bayarri, Jordi.
21ACL033. ESTUDIO DE FASE III, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CON DOBLE ENMASCARAMIENTO Y DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD FENEBRUTINIB EN COMPARACIÓN CON TERIFLUNOMIDA EN PACIENTES ADULTOS ESCLEROSIS MÚLTIPLE RECURRENTE (EMR). Roche Farma, S.A. Budget: 112.560€. 2021- . PI: Martínez Yélamos, Sergio.

Technology transfer

More information

PROJECTS

Title: Activation of the resolution programs of inflammation as a novel therapeuthic approach for the treatment of amyotrophic lateral sclerosis
PI: Povedano Padanes, Mònica
Coordinator: Universitat Autònoma de Barcelona- UAB (Project Leader: Dr. Rubèn López Vales)
Call reference: Health Research 2017 Call for proposals, expediente: HR17-00777
Funder: Fundació “la Caixa”